Total Body Photography and Sequential Digital Dermoscopy for Melanoma Diagnosis

2020 ◽  
pp. 121-126
Author(s):  
Maria Antonietta Pizzichetta ◽  
Ignazio Stanganelli
Keyword(s):  
Melanoma Diagnosis ◽  
Total Body ◽  
Digital Dermoscopy

Digital Dermoscopy Photographs Outperform Handheld Dermoscopy in Melanoma Diagnosis

2016 ◽  
Vol 20 (6) ◽  
pp. 602-605 ◽  
Author(s):  
Danielle Mintsoulis ◽  
Jennifer Beecker
Keyword(s):  
High Risk ◽  
Medical Records ◽  
Ottawa Hospital ◽  
Melanoma Diagnosis ◽  
Pigmented Lesion ◽  
Clinical Advantage ◽  
The Difference ◽  
Total Body ◽  
Digital Dermoscopy

Background: Pigmented lesion clinics (PLCs) that use technology such as digital dermoscopy and total-body photography are thought to confer a clinical advantage for patients at high risk of developing melanoma over general dermatology clinics (GDCs) with regular dermoscopy. Objective: To examine the difference between depths of melanomas diagnosed in a PLC and a GDC. Methods: Medical records from 257 patients at the PLC at The Ottawa Hospital and 441 patients from a GDC were reviewed. Results: Invasive melanoma was less frequent than in situ melanoma at the PLC (7.14% vs 38.27%; P = .02). The average Breslow depth for melanomas at the PLC was also smaller compared with the GDC (0.0371 vs 0.3450 mm; P = .02). Conclusions: The use of digital dermoscopy and total-body photography together in a PLC appears to be an effective way to monitor patients at high risk of melanoma.

scholarly journals Total Body Photography and Sequential Digital Dermoscopy in Pregnant Women

2019 ◽  
pp. 126-131
Author(s):  
Gabriela M. Martins-Costa ◽  
Renato Bakos
Keyword(s):  
Differential Diagnosis ◽  
Cohort Study ◽  
Pregnant Women ◽  
Skin Type ◽  
Type Ii ◽  
Third Trimester ◽  
Melanocytic Nevi ◽  
Vascular Structures ◽  
Total Body ◽  
Digital Dermoscopy

Background: Melanocytic nevi can vary in size and number in pregnant women, and the differential diagnosis with melanoma may be challenging. Objectives: To describe changes in total body photography of pregnant women and dermoscopy aspects of their nevi. Methods: A prospective cohort study with 703 melanocytic nevi from 18 women was performed, comparing them in the first and third trimester of pregnancy. Images were analyzed between the 2 periods for changes in dermoscopic aspects. Results: Total body photography images indicated that 44% of patients had new lesions. Regarding the observed changes, there were symmetric or regular changes of the network (23% of cases), occurrence of new globules/dots (12.4%), new vascular structures (3.2%), new streaks (1.7%), and new structureless area (1.0%). Moreover, 55.0% of the nevi increased in size. Enlarging of the nevi was observed mostly on the abdomen (87.1%; P < 0.001) and showed more network changes (27.1%; P = 0.014) and formation of new globules and dots (16.0%; P < 0.001). Patients with a risk of developing melanoma presented more frequently enlarged nevi (45%; P = 0.019). The association between streak formation and skin type was significant (P = 0.012) and was more frequent in skin type II (2.7%), when compared with skin types III (1.3%) and IV (0%).

Metastatic melanoma patients: Prospective follow-up of pigmented lesions under vemurafenib by digital dermoscopy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 9093-9093
Author(s):  
Marie Perier-Muzet ◽  
Stephane Dalle ◽  
Gerard Duru ◽  
Luc Thomas ◽  
Sebastien Debarbieux ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Second Primary ◽  
External Diameter ◽  
Inform Consent ◽  
Cutaneous Side Effects ◽  
Pigmented Lesions ◽  
Total Body ◽  
The Impact ◽  
Digital Dermoscopy

9093 Background: Vemurafenib is the first approved by the FDA BRAF V600 inhibitor for the treatment of metastatic melanoma. Many cutaneous side-effects such as squamous cell carcinoma, xerosis, photosensitivity are observed. We first reported the occurrence of second primary melanomas (SPM) under BRAF inhibition. These SPM were shown to be wild-type for BRAF. The exact occurrence of these changes is still unknown. We wanted then to explore prospectively the impact of vemurafenib on cutaneous pigmented lesions using sequential digital dermoscopy. Methods: We registered prospectively following inform consent the pigmented lesions of patients under vemurafenib. We examined the total body surface and captured from 9 to 134 pigmented lesions on 24 patients. Each single lesion was followed monthly from vemurafenib initiation to vemurafenib disruption due to disease progression. Dermoscopic modifications of the melanocytic lesions including external diameter, dermoscopical pattern, pigmentation, network thickness, dots distribution and keratosis appearance were analyzed. Results: The median duration of dermoscopic follow up was 6,9 months ( range from 2 to 16 months), 1098 pigmented lesions were included. At least one modification occurred in 56% of the lesions. Most frequent modifications were the occurrence of dark globules (56%), change in the pigmentation coloration (47%), variations in network thickness (32%), increase of the external size (20,1%), onset of black areas (14%), onset of keratosis (4,4%). Up to 5,3% of lesions spontaneously disappeared; 21 excisions were performed due to significant dermoscopic changes and revealed 10 early melanomas in 5/24 patients (20,8%). The 11 remaining lesions were benign. Conclusions: More than fifty percent of the patients under vemurafenib will experiment significant modifications on their pigmented lesions. In our experience 10/21 removed lesions were early melanomas that could not be otherwise diagnosed using naked-eyes examinations only. Digital dermoscopy is one of the tool that can be use to discriminate earlier the modifications. Such careful monitoring will improved the safety when evaluating BRAF inhibitors in adjuvant setting.

scholarly journals Total Body Photography and Sequential Digital Dermoscopy Imaging for Melanoma Surveillance in Patients Starting Natalizumab for Multiple Sclerosis

2021 ◽  
Vol 3 (2) ◽  
Author(s):  
Tyler Nussinow ◽  
Amanda Robinson ◽  
Biljana Beretich ◽  
Kathryn Stevens ◽  
Elizabeth Seiverling
Keyword(s):  
Multiple Sclerosis ◽  
Total Body ◽  
Melanoma Surveillance ◽  
Digital Dermoscopy

scholarly journals Evaluation of the efficacy of 3D total-body photography with sequential digital dermoscopy in a high-risk melanoma cohort: protocol for a randomised controlled trial

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e032969 ◽  
Author(s):  
Clare Amy Primiero ◽  
Aideen M McInerney-Leo ◽  
Brigid Betz-Stablein ◽  
David C Whiteman ◽  
Louisa Gordon ◽  
...  
Keyword(s):  
High Risk ◽  
Controlled Trial ◽  
Clinical Care ◽  
Melanoma Risk ◽  
Surveillance Programme ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Total Body ◽  
Randomised Controlled ◽  
Digital Dermoscopy

IntroductionMelanoma is Australia’s fourth most common cancer. Early detection is fundamental in maximising health outcomes and minimising treatment costs. To date, population-based screening programmes have not been justified in health economic studies. However, a skin surveillance approach targeting high-risk individuals could improve the cost-benefit ratio.Methods and analysisThis paper describes a 2-year longitudinal randomised controlled trial (RCT) to compare routine clinical care (control) with an intensive skin surveillance programme (intervention) consisting of novel three-dimensional (3D) total-body photography (TBP), sequential digital dermoscopy and melanoma-risk stratification, in a high-risk melanoma cohort. Primary outcomes will evaluate clinical, economic and consumer impact of the intervention. Clinical outcomes will evaluate differences in the rate of lesion excisions/biopsies per person, benign to malignant ratio for excisions and thickness of melanomas diagnosed. A health economic analysis using government data repositories will capture healthcare utilisation and costs relating to skin surveillance. Consumer questionnaires will examine intervention acceptability, the psychological impact, and attitudes towards melanoma risk and sun protective behaviour. Secondary outcomes include the development of a holistic risk algorithm incorporating clinical, phenotypic and genetic factors to facilitate the identification of those most likely to benefit from this surveillance approach. Furthermore, the feasibility of integrating the intervention with teledermatology to enhance specialist care in remote locations will be evaluated. This will be the first RCT to compare a targeted surveillance programme utilising new 3D TBP technology against current routine clinical care for individuals at high risk of melanoma.Ethics and disseminationThis study has received Human Research Ethics Committee (HREC) approval from both Metro South Health HREC (HREC/17/QPAH/816) and The University of Queensland HREC (2018000074).Trial registration numberANZCTR12618000267257; Pre-results.

scholarly journals The Future of Precision Prevention for Advanced Melanoma

2022 ◽  
Vol 8 ◽  
Author(s):  
Katie J. Lee ◽  
Brigid Betz-Stablein ◽  
Mitchell S. Stark ◽  
Monika Janda ◽  
Aideen M. McInerney-Leo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Stratification ◽  
Clinical Phenotype ◽  
Advanced Melanoma ◽  
Consumer Trust ◽  
Melanoma Risk ◽  
Melanoma Diagnosis ◽  
Computer Aided ◽  
Total Body ◽  
Personalized Risk

Precision prevention of advanced melanoma is fast becoming a realistic prospect, with personalized, holistic risk stratification allowing patients to be directed to an appropriate level of surveillance, ranging from skin self-examinations to regular total body photography with sequential digital dermoscopic imaging. This approach aims to address both underdiagnosis (a missed or delayed melanoma diagnosis) and overdiagnosis (the diagnosis and treatment of indolent lesions that would not have caused a problem). Holistic risk stratification considers several types of melanoma risk factors: clinical phenotype, comprehensive imaging-based phenotype, familial and polygenic risks. Artificial intelligence computer-aided diagnostics combines these risk factors to produce a personalized risk score, and can also assist in assessing the digital and molecular markers of individual lesions. However, to ensure uptake and efficient use of AI systems, researchers will need to carefully consider how best to incorporate privacy and standardization requirements, and above all address consumer trust concerns.

Sign in / Sign up

Export Citation Format

Share Document